Application of biomedical cell products based on natural killer cells and cytokine-induced killer cells for the treatment of oncological diseases

Cellular immunotherapy has become an essential part of modern concepts of oncology treatment. One of the promising tool of immunotherapy in the treatment of cancer is the use of biomedical cell products (BMCP) based on natural killer cells (NK-cells) and cytokine-induced killer cells (CIKc). NK-cells are a unique population of innate lymphoid cells that identify tumor cells and play a key role in anticancer immunity through their cytotoxicity mechanisms. CIKc share the immunofunctional properties both of T-lymphocytes and NK cells; they do not require antigen-specific priming to recognize tumor cells and can be quickly cultured in vitro. The purpose of this review is to evaluate the available literature describing adoptive immunotherapy for BMCP based on NK-cells and CIKc.